课题基金 / 基金详情

项目摘要

项目成果

Clarence J. Peters的其他基金

相似基金

相关文献

中文摘要
翻译
该BSL-4核心提供了基础设施以允许在气溶胶感染性上执行安全的工作, 潜在的致命毒剂。它由两个高度封闭的实验室的机械保障组成, 提供BSL-4操作方面的培训,并协助实验室内的操作。一般来说, 调查人员将在实验室内工作,但约20%的努力将用于挑战 使用已建立的动物模型测试新开发的疫苗和疗法的实验。部分 该核心位于德克萨斯州圣安东尼奥的西南生物医学研究基金会(SF BR),那里 有1200英尺2的BSL-4实验室空间可用。另一部分计划于6月完成, 2003年,将在德克萨斯州加尔维斯顿的德克萨斯大学医学分部提供2000英尺2。SFBR设施 自2000年3月开始运作,为微生物作业提供空间,以及 为啮齿动物和小型非人灵长类动物提供住所。UTMB将有1000英尺2英寸,主要用于动物 1000英尺2主要用于微生物学研究。这两家公司都可以使用高强度的伽马辐射器 将样品灭活,以便在BSL-4实验室外进行进一步分析。此核心对于以下工作至关重要 出血热病毒和多药耐药高致病菌。
英文摘要
This BSL-4 core provides the infrastructure to permit safe work to be performed on aerosol-infectious, potentially lethal agents. It consists of the mechanical safeguards of two high-containment laboratories, the provision of training in BSL-4 operations, and assistance in operations within the laboratories. Generally, the investigators will work within the laboratory, but about 20% of the effort will be devoted to challenge experiments using established animal models to test newly developed vaccines and therapeutics. Part of this core is located at Southwest Foundation for Biomedical Research (SF BR) in San Antonio, TX where 1200 ft 2 of BSL-4 laboratory space is available. The other component is scheduled for completion in June, 2003 and will provide 2000 ft 2 at the University of Texas Medical Branch, Galveston, TX. The SFBR facility has been in operation since March of 2000 and provides space for microbiological operations as well as housing for rodents and small non-human primates. UTMB will have 1000 ft 2devoted primarily to animals and 1000 ft 2 mainly used to for microbiology. Both have access to a high intensity gamma irradiator allowing inactivation of samples for further analysis outside the BSL-4 laboratory. This core is essential for work on the hemorrhagic fever viruses and multidrug resistant highly pathogenic bacteria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
Rift Valley Fever Vaccine Development of Animal Models and Optimize Production
Passive Immunotherapeutics for Select Agents
海外基金